RENAAL
2001
Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan
In 1,513 patients with type 2 diabetes and nephropathy, losartan reduced the composite of creatinine doubling, ESRD or death compared with placebo.
Result
Primary endpoint: Doubling of serum creatinine, ESRD or death
16% relative risk reduction (p=0.02); ESRD alone reduced 28% (p=0.002).
- Subtopic
- RAAS blockade
- Design
- Double-blind RCT, median 3.4-year follow-up
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Brenner BM, et al. N Engl J Med. 2001;345(12):861-869.doi 10.1056/NEJMoa011161
Discussion & critique
First registration of an ARB for diabetic nephropathy; underpins the KDIGO 1A recommendation for ARBs in T2DM with albuminuria.